GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.52
+1.27 (+1.89%)
At close: 4:00PM EST

68.45 -0.07 (-0.10%)
After hours: 6:47PM EST

Stock chart is not supported by your current browser
Previous Close67.25
Open67.19
Bid68.21 x 3000
Ask68.52 x 800
Day's Range67.03 - 68.71
52 Week Range60.32 - 89.54
Volume6,899,386
Avg. Volume7,797,573
Market Cap88.639B
Beta (3Y Monthly)1.34
PE Ratio (TTM)56.86
EPS (TTM)1.21
Earnings DateFeb 4, 2019
Forward Dividend & Yield2.28 (3.36%)
Ex-Dividend Date2018-12-13
1y Target Est85.15
Trade prices are not sourced from all markets
  • Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
    Zacks3 hours ago

    Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

    Gilead Sciences (GILD) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day.

  • Here's How The Government Shutdown Will Affect These Medical Stocks
    Investor's Business Daily4 hours ago

    Here's How The Government Shutdown Will Affect These Medical Stocks

    The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.

  • Markit12 hours ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.21 billion over the last one-month into ETFs that hold GILD are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why Verastem Tumbled 34.1% in December
    Motley Fool4 days ago

    Here's Why Verastem Tumbled 34.1% in December

    Investors have been worried about a difficult new drug launch.

  • NASH Space in Focus in 2019 as Firms Look to Diversify
    Zacks4 days ago

    NASH Space in Focus in 2019 as Firms Look to Diversify

    NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

  • Have Insiders Been Selling Gilead Sciences, Inc. (NASDAQ:GILD) Shares?
    Simply Wall St.6 days ago

    Have Insiders Been Selling Gilead Sciences, Inc. (NASDAQ:GILD) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Value Added: 7 Top Stocks for 2019
    Kiplinger6 days ago

    Value Added: 7 Top Stocks for 2019

    Making money in the stock market this year is going to take all the skill and luck you can muster. The global economy is slowing, a trade war with China still lingers despite negotiations, and the Federal Reserve remains likely to raise short-term interest rates, albeit slowly. But you still can find promising investments. To identify some of the top stocks right now, I interviewed Jerome Dodson, manager of Parnassus Endeavor Fund (PARWX) and founder of the Parnassus funds. Based in San Francisco, Parnassus is the largest U.S. fund firm focused on buying good stocks that are also, in the firm's view, good corporate citizens in terms of the environment, social and corporate governance issues. More to the point, Dodson's fund has a first-class record. Endeavor returned an annualized 16.3% over the past 10 years - an average of 3.1 percentage points per year better than the Standard & Poor's 500-stock index. Dodson, 75, is a contrarian investor who loves to pounce on stocks that have been pummeled. Given the selloff, this is precisely Dodson's kind of market. Read on for his seven top stocks for 2019. ### SEE ALSO: 19 Best Retirement Stocks to Buy in 2019

  • Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
    Zacks6 days ago

    Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

    It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

  • Cell therapy pioneer eyes Bay Area manufacturing
    American City Business Journals6 days ago

    Cell therapy pioneer eyes Bay Area manufacturing

    The South San Francisco company, which has quickly grown to 105 employees and raised more than a half-billion dollars, plans to site a cell manufacturing facility in the Bay Area.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $20.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The 9 Best Stocks of America’s Last Bear Market
    Kiplinger7 days ago

    The 9 Best Stocks of America’s Last Bear Market

    It's official. The Nasdaq Composite has waded all the way into bear-market territory, now down 20% from its late-September peak. The Dow Jones Industrial Average and the Standard & Poor's 500-stock index aren't far behind. Whether the fourth-quarter selloff is merited doesn't entirely matter. If the crowd believes the rout suffered over the course of the past three months is the shape of things to come, stocks will lose more ground as investors create the very bear market they fear. It's a self-fulfilling prophecy. But here at the precipice of seeing the market's condition shift from bad to worse, remember: Not all stocks have to lose ground, even if the tide is going out. One only has to look at the nine big stocks that managed to gain ground between October 2007 and March 2009 - America's last bear market - to appreciate that some companies have staying power even in rough environments. Here are nine S&P; 500 stocks that actually gained in the face of the 2007-09 bear market. Notice in all nine cases, there was something unique about these organizations that shielded them from the full impact of economic woe. And in some cases, they still look properly positioned to fight off another bear attack. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Investing.com7 days ago

    Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close

    Investing.com - Union Pacific , Motorcar Parts of America and Nektar Therapeutics surged on Tuesday, underpinning a second-straight day of gains in the broader market.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $20.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 7 Things to Expect for Gilead Sciences in 2019
    Motley Fool8 days ago

    7 Things to Expect for Gilead Sciences in 2019

    The big biotech's executives spill the beans on plans for the new year at the J.P. Morgan Healthcare Conference.

  • Business Wire8 days ago

    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)

    Gilead Sciences, Inc. (GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection with decompensated cirrhosis, and for patients with chronic HCV infection without cirrhosis or with compensated cirrhosis who have had prior treatment with a direct-acting antiviral therapy (DAA).

  • Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
    Zacks8 days ago

    Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

    Gilead Sciences (GILD) closed at $68.56 in the latest trading session, marking a +0.45% move from the prior day.

  • Biotech's big conference living up to reputation with big deals, big costs
    American City Business Journals8 days ago

    Biotech's big conference living up to reputation with big deals, big costs

    Deals are rolling out during the first day of the J.P. Morgan Healthcare Conference and so, too, are the hotel meeting costs.

  • Why Agenus Stock Is Spiking Today
    Motley Fool8 days ago

    Why Agenus Stock Is Spiking Today

    Eli Lilly's acquisition of Loxo Oncology lit a fire underneath the cancer immunotherapy company today..

  • InvestorPlace8 days ago

    As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock

    AbbVie (NASDAQ:ABBV) is basically a one-trick pony. The trick is an immunosuppressant called Humira, prescribed to fight rheumatoid arthritis and other conditions. It's the best-selling drug in the world, bringing in $18.4 billion in 2017, but that might not be sufficient to support the future of AbbVie stock. While protected against direct competition in the U.S. until 2023, Humira is already facing biosimilars in Europe, as its protections there disappear. AbbVie has been milking Humira for dividends, $4.28 per year, a yield of 4.76%. The stock looks cheap, at 18 times earnings, and has held up well during the bear market, down just 8.7% over the last six months while the average NASDAQ stock is down nearly 15%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The question for investors is whether AbbVie stock is the kind of defensive play you want to be making in 2019. * 9 A-Rated Safety Stocks for a Grossly Oversold Market ### AbbVie Stock Shows Signs of Life Like an aging doyenne who can still dance at the ball, AbbVie's situation still looks good. Despite a price tag of up to $2,600 per month, Humira continues to sell because it has been approved to treat many diseases. Not just arthritis, but Crohn's Disease, ulcerative colitis and even the heartbreak of psoriasis are treated with it. While its U.S. patent expired in 2016, AbbVie has been able to extend its U.S. rights into the next decade through ancillary patents and aggressive lawyering. Rather than ending, its sales are expected to just trend down slowly. While Europe this year will have biosimilars from privately-held Boehringer Ingelheim, Sandoz, Amgen (NASDAQ:AMGN) and Samsung Bioepis, Humira's revenues won't be destroyed, only reduced. AbbVie, which was spun out of Abbott Laboratories (NYSE:ABT) in 2013, has also been building its own drug pipeline, with new dermatology drugs on the way, as well as anti-cancer drugs. It has a treatment for Hepatitis C, Mavyret, which competes directly with Harvoni from Gilead Sciences (NASDAQ:GILD). ### The Long Look at AbbVie Stock Still, like that old doyenne, AbbVie knows the sunset for Humira is coming. It's like an old oil field. You can frack it, but those wells, too, won't produce forever. Early in the next decade, AbbVie will be facing a problem similar to the one Pfizer (NYSE:PFE) did early in this decade, when the rights on Lipitor expired in 2011. There are a host of strategies for keeping such drugs alive, in a financial sense, and AbbVie is engaging in, or preparing to engage, in all of them. But Humira is as dominant as Lipitor once was, with twice the sales of the next largest-selling drug, Celgene's (NASDAQ:CELG) Revlimid, a cancer drug. AbbVie will need several hits to replace Humira, and time is running out. AbbVie is the big winner in immunosuppressants, originally developed to prevent rejection of new organs but now offered against a host of autoimmune conditions, but as its own experience with Mavyret shows, European regulators and American pharmacy benefit managers have ways to fight back against skyrocketing prices. The effectiveness of these tools, pitting drug against drug and choosing a formulary based at least partly on price, is going to increase with competition over the coming years and may be a bigger overhang on AbbVie's growth than its patent expiration. ### The Bottom Line on AbbVie Stock For now, the good times roll on. AbbVie is due to report earnings Jan. 25, expecting sales of $8.36 billion for a 2018 total of $32.8 billion , 16% ahead of 2017's $28.2 billion. Net income of $1.92 per share will bring that total to $6.92 per share for the year. But, as they say of both athletes and great beauties, Father Time is undefeated. AbbVie still faces a patent cliff, and growing opposition to rising prices. Nothing lasts forever. What works this year may not work next year. Know that before you buy AbbVie stock. Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Top Stock Picks From the Street's Best Analysts * 7 Tech Stocks Without China Exposure * 5 Strong-Buy Stocks That Crushed 2018 Compare Brokers The post As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock appeared first on InvestorPlace.

  • Merck loses bid to revive $200 million Gilead verdict at U.S. high court
    Reuters8 days ago

    Merck loses bid to revive $200 million Gilead verdict at U.S. high court

    The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs. A jury awarded Merck $200 million in 2016 after finding Gilead's Hepatitis C drugs Sovaldi and Harvoni infringed two of its patents, but a judge later ruled the patents unenforceable because of a pattern of misconduct by Merck including lying under oath by one of its in-house lawyers. Merck had urged the Supreme Court to place limits on the doctrine of "unclean hands" that can prevent plaintiffs from winning lawsuits if they acted in bad faith.

  • Merck loses bid to revive $200 million Gilead verdict at U.S. high court
    Reuters8 days ago

    Merck loses bid to revive $200 million Gilead verdict at U.S. high court

    The U.S. Supreme Court on Monday handed a defeat to Merck & Co (MRK.N) by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc (GILD.O) in a dispute involving blockbuster hepatitis C drugs. A jury awarded Merck $200 million in 2016 after finding Gilead's Hepatitis C drugs Sovaldi and Harvoni infringed two of its patents, but a judge later ruled the patents unenforceable because of a pattern of misconduct by Merck including lying under oath by one of its in-house lawyers. Merck had urged the Supreme Court to place limits on the doctrine of "unclean hands" that can prevent plaintiffs from winning lawsuits if they acted in bad faith.

  • Gilead (GILD) Collaborates With Yuhan for NASH Candidates
    Zacks8 days ago

    Gilead (GILD) Collaborates With Yuhan for NASH Candidates

    Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.

  • Better Buy: Gilead Sciences vs. Amgen
    Motley Fool9 days ago

    Better Buy: Gilead Sciences vs. Amgen

    Strong cash flows and juicy dividends set these biotech stocks ahead of their peers, but which is the better pick now?

  • Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
    Business Wire9 days ago

    Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

    Yuhan) today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Under the agreement, Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries, with the exception of the Republic of Korea where Yuhan will retain certain commercialization rights. Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development.

  • 2019 J.P. Morgan Healthcare Conference Roundup
    Motley Fool9 days ago

    2019 J.P. Morgan Healthcare Conference Roundup

    All your Motley Fool coverage of the 2019 J.P. Morgan Healthcare Conference in one place.